Author

M. Gumus

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study

Background In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy. We report efficacy and safety outcomes after extended...

C. Rudin, M.-J. Ahn, M. Schuler et al. · Annals of Oncology · 0 citations

Open access Oct 2026

CT-defined sarcopenia and outcomes in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors

Sarcopenia is increasingly recognized as a potential prognostic factor in patients with cancer, but its clinical significance in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors remains uncertain. This study investigated the association between CT-defined sarcopenia and clinical outcomes in this po...

Zeynep Alaca Topçu, Zehra Sucuoğlu İşleyen, Ismail Yurtsever et al. · Frontiers in Medicine · 0 citations

Open access Sep 2026

Pretreatment CONUT Score and Overall Survival in Patients with Metastatic Pancreatic Adenocarcinoma Receiving First-Line Chemotherapy: A Retrospective Cohort Study

An elevated pretreatment CONUT score was associated with shorter overall survival in this selected chemotherapy-treated cohort, and as a readily available laboratory-based index, CONUT may provide additional prognostic information; however, prospective studies are needed to determine whether it adds value beyond establ...

Zeynep Alaca Topçu, Serhat Demirer, T. Baydaş et al. · Medicina · 0 citations